RTP Mobile Logo

Sunday, March 31, 2019, Atlanta, Georgia, 7:00 PM – 9:00 PM

Leveraging the Immune System for Therapeutic Benefit in Non-Small Cell Lung Cancer — Scientific Insights, Clinical Applications and Future Directions

Event Details

Location:
Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, GA 30303
Hotel Phone: (404) 577-1234

Time:
6:30 PM – 7:00 PM — Registration and Buffet Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room:
Centennial I-II (Ballroom Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Vali A Papadimitrakopoulou, MD
Jay and Lori Eisenberg Distinguished Professor
Section Chief, Thoracic Medical Oncology
Professor of Medicine
Department of Thoracic/HN Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Naiyer Rizvi, MD
Price Family Professor of Medicine at CUMC
Columbia University Medical Center
Director, Thoracic Oncology Program
Co-Director, Immunotherapy in the
Department of Medicine
Research Director, Price Family Comprehensive Center for Chest Care at NewYork-Presbyterian Hospital
New York, New York

David R Spigel, MD
Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee


Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

This symposium is accredited by Research To Practice and supported by a grant from AstraZeneca Pharmaceuticals LP. This is not an official program of the American Association for Cancer Research Annual Meeting.

Agenda

Meeting Agenda and Format

This unique activity will feature the perspectives of 4 leading researchers in the management of lung cancer. Each faculty member will deliver a presentation reviewing recently published research data and ongoing clinical trials related to the use of approved and developmental immunotherapeutic approaches in the treatment of non-small cell lung cancer. After each presentation, moderated panel discussion will take place to generate other relevant perspectives and dialogue. In an effort to enhance interactivity and help attendees tailor the learning experience to meet their own needs, we will invite participants to use networked iPads provided to make comments, ask questions and connect with peers in real time in a specially designed audience chat room.

MODULE 1: Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Langer

  • Historical outcomes associated with standard concurrent chemoradiation therapy and consolidation chemotherapy in patients with unresectable Stage III disease
  • Preclinical and clinical research efforts documenting the synergistic effect of chemoradiation therapy and immune checkpoint inhibition
  • Design of, eligibility criteria for and key efficacy and safety findings from the Phase III PACIFIC trial evaluating the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
  • Biologic rationale for the benefit observed with durvalumab in prespecified subgroups (eg, histology, PD-L1 status, presence of an actionable mutation, smoking status) in the PACIFIC trial
  • Patient selection for and practical implementation of sequential durvalumab in the management of unresectable Stage III NSCLC

MODULE 2: Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-1/PD-L1 Antibodies for Locally Advanced and Metastatic Disease — Dr Papadimitrakopoulou

  • Pathophysiology of common and uncommon adverse events observed with the use of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches in the locally advanced and metastatic settings
  • Optimal timing for the use of durvalumab consolidation; impact of underlying pneumonitis on the potential introduction of anti-PD-L1 therapy in this setting
  • Rates of Grade 3/4 adverse events (AEs), including pneumonitis and other immune-mediated AEs, and treatment discontinuation among patients receiving durvalumab in the PACIFIC study
  • Recent ASCO guidelines on the management of immune-related AEs in patients receiving immune checkpoint inhibitor therapy; applicability to patients with Stage III disease
  • Effects of immune therapies in patients with prior autoimmune diseases or who have undergone solid organ transplant

MODULE 3: Current Application of Immune Checkpoint Inhibitors in the Treatment of Metastatic NSCLC; Role for Patients with Actionable Tumor Mutations — Dr Spigel

  • Basic and clinical research supporting the evaluation of chemoimmunotherapy combinations: Dual role of cytotoxicity and immune activation from chemotherapy
  • Implications of the Phase III KEYNOTE-042 and KEYNOTE-189 trial results; clinical and biologic factors affecting the selection of anti-PD-1 monotherapy versus combined chemotherapy/immune checkpoint inhibition
  • Key safety and efficacy results from the Phase III IMpower130 and 132 trials of the addition of atezolizumab to chemotherapy for metastatic nonsquamous NSCLC
  • Biologic rationale for the potential synergy between tumor immunotherapy and anti-angiogenic therapy; available evidence supporting the immune modulatory effect of VEGF inhibition
  • Key efficacy and safety findings from the Phase III IMpower150 study evaluating atezolizumab/bevacizumab in combination with carboplatin/paclitaxel for chemotherapy-naïve advanced nonsquamous NSCLC; implications of the recent FDA approval of this combination and proposed mechanisms of its effectiveness in specific subsets (eg, patients with liver metastases, those with actionable tumor mutations)
  • State of the tumor microenvironment in oncogene-addicted NSCLC; level of mutational load in patients with EGFR, ALK and other driver mutations and relationship with responsiveness to immune checkpoint inhibitors
  • Role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced squamous NSCLC; results from the Phase III KEYNOTE-407 and IMpower131 trials

MODULE 4: Future Directions for Clinical and Translational Research — Dr Rizvi

  • Rationale for the evaluation of anti-PD-1/PD-L1 antibodies in nonmetastatic settings beyond consolidation therapy for locally advanced disease (eg, neoadjuvant therapy, adjuvant treatment after resection)
  • Shaping of T-cell costimulation with the use of combined anti-PD-1/PD-L1 and anti-CTLA-4 therapy; available research evidence evaluating these combinations
  • Available data documenting the correlation between tumor mutational burden and response to immune checkpoint inhibitors; other established and potential predictors of response (eg, microsatellite instability, tumor-infiltrating lymphocytes)
  • Presence and prevalence of other inhibitory (eg, LAG-3, TIM-3) and activating (eg, OX-40, GITR) immune pathways; preclinical and early clinical work supporting the evaluation of novel agents targeting these pathways alone or in combination with anti-PD-1/PD-L1 antibodies in NSCLC
  • Modulation of tumor responses to checkpoint inhibitor therapy by the gut microbiome

CE Information

Target Audience:
This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Analyze the biologic basis for the investigation of immune checkpoint inhibitors in the treatment of nonmetastatic and advanced non-small cell lung cancer (NSCLC).
  • Appraise the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Review published research data documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy for newly diagnosed metastatic NSCLC.
  • Evaluate the biology of oncogene-addicted tumors to optimally employ anti-PD-1/PD-L1 antibody therapy in the care of patients with metastatic NSCLC and a targetable mutation.
  • Recognize current investigational efforts to identify additional biomarkers of response to checkpoint inhibition in patients with NSCLC, and consider how they may be applied in future clinical practice.
  • Understand the biologic rationale for and published research data with the use of combination regimens targeting multiple immune checkpoints, and, where applicable, refer patients for ongoing research studies.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies for NSCLC, and counsel appropriate patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Location

Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, GA 30303
Hotel Phone: (404) 577-1234

Meeting Room:
Centennial I-II (Ballroom Level)

 

Registration

This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.